Advancements in COVID Vaccines: Strong Immune Response, Efficacy Against Long COVID, Cost-Effectiveness, and Promising Intranasal Option

A phase I study presented at the IDWeek meeting showed that an intranasal COVID-19 vaccine candidate, CoviLiv, produced a strong immune response in healthy adults, with participants exhibiting increased levels of spike-specific antibodies and interferon-gamma response. The vaccine does not require cold chain storage and could potentially increase access to vaccinations in underserved areas. Additionally, researchers discussed the use of wastewater surveillance as a tool to predict outbreaks of respiratory viruses such as influenza and respiratory syncytial virus (RSV). Lastly, a maternal RSV vaccine was highlighted as a potential strategy to reduce hospitalizations and costs associated with RSV infection in infants.